Sanofi Pasteur Inc.

Pascal Loubiere

Fabien Barbirato

Jérome Le Hir

Nicholas Lindley

The invention concerns a method for producing, on an industrial scale, capsular polysaccharide oftype b (PRP) intended for vaccine purposes, according to which a strain oftype b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: &#x2014;one source of carbon, &#x2014;protoporphyrin, &#x2014;salts, &#x2014;amino acids, &#x2014;NAD or NADH, &#x2014;vitamins, &#x2014;means for regulating the pH, characterized in that said culture medium is chemically defined.

[object Object]

The invention concerns a method for producing, on an industrial scale, capsular polysaccharide oftype b (PRP) intended for vaccine purposes, according to which a strain oftype b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: &#x2014;one source of carbon, &#x2014;protoporphyrin, &#x2014;salts, &#x2014;amino acids, &#x2014;NAD or NADH, &#x2014;vitamins, &#x2014;means for regulating the pH, characterised in that said culture medium is chemically defined.

Growing community of inventors

Donneville, France

Pascal Loubiere